Abstract
Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.
MeSH terms
-
Aged, 80 and over
-
Antineoplastic Agents, Alkylating / adverse effects*
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use
-
Glioblastoma / drug therapy
-
Humans
-
Male
-
Pneumocystis carinii
-
Pneumonia, Pneumocystis / chemically induced*
-
Pneumonia, Pneumocystis / diagnosis
-
Pneumonia, Pneumocystis / physiopathology
-
Temozolomide
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide